Affordable Access

deepdyve-link
Publisher Website

Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases.

Authors
  • Jiang, Jiao1, 2
  • Zhao, Ming1, 2
  • Chang, Christopher3, 4
  • Wu, Haijing5, 6
  • Lu, Qianjin7, 8
  • 1 Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. , (China)
  • 2 Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. , (China)
  • 3 Division of Pediatric Immunology and Allergy, Joe DiMaggio Children's Hospital, Hollywood, FL, 33021, USA.
  • 4 Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA, 95616, USA.
  • 5 Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. [email protected] , (China)
  • 6 Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. [email protected] , (China)
  • 7 Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. [email protected] , (China)
  • 8 Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China. [email protected] , (China)
Type
Published Article
Journal
Clinical Reviews in Allergy & Immunology
Publisher
Springer-Verlag
Publication Date
Jun 17, 2020
Identifiers
DOI: 10.1007/s12016-020-08798-2
PMID: 32557263
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Type I interferons (IFN-Is) are a very important group of cytokines that are produced by innate immune cells but also act on adaptive immune cells. IFN-Is possess antiviral, antitumor, and anti-proliferative effects, as well are associated with the initiation and maintenance of autoimmune disorders. Studies have shown that aberrantly expressed IFN-Is and/or type I IFN-inducible gene signatures in the serum or tissues of patients with autoimmune disorders are linked to their pathogenesis, clinical manifestations, and disease activity. Type I interferonopathies with mutations in genes impacting the type I IFN signaling pathway have shown symptoms and characteristics similar to those of systemic lupus erythematosus (SLE). Furthermore, both interventions in animal models and clinical trials of therapies targeting the type I IFN signaling pathway have shown efficacy in the treatment of autoimmune diseases. Our review aims to summarize the functions and targeted therapies (as well as clinical trials) of IFN-Is in both adult and pediatric autoimmune diseases, such as SLE, pediatric SLE (pSLE), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), juvenile dermatomyositis (JDM), Sjögren syndrome (SjS), and systemic sclerosis (SSc), discussing the potential abnormal regulation of transcription factors and epigenetic modifications and providing a potential mechanism for pathogenesis and therapeutic strategies for future clinical use.

Report this publication

Statistics

Seen <100 times